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INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia world-
wide, affecting 1% to 2% of the general population, with an 
increasing prevalence and incidence in the elderly [1–3]. 
“Silent AF” is diagnosed in individuals who are asymptomatic 
and is usually discovered based on incidental electrocardio-
graphic (ECG) testing [4, 5]. The frequency of silent AF in the 
general population is less certain, ranging from 1% to 10%, 
and is deemed the cause of 4.4% of all episodes of ischaemic 
stroke [1, 6]. While long-term ECG monitoring allows early 
detection of AF in larger groups of individuals compared with 
short-term ECG recordings, there are currently no registered 
or approved non-invasive systems for heart rhythm monitor-
ing for long-term use.
The aims of the NOMED-AF study are to determine the 
prevalence of AF in the Polish population using long-term ECG 
monitoring in individuals aged ≥ 65 years, and to ascertain 
the independent risk factors for the clinically symptomatic 
and asymptomatic forms of AF. 
METHODS
The NOMED-AF study is a cross-sectional, observational 
study aimed at the assessment of the prevalence of AF and 
its correlation with cardiovascular disease risk factors in the 
Polish population, based on a representative sample of adults 
aged ≥ 65 years. The main objective of the survey is to evalu-
ate the prevalence of AF and the associated comorbidities.
The assessment of AF prevalence will be performed 
with the use of an ECG monitoring system developed 
and validated during the first and second phases of the 
project as well as a detailed questionnaire, follow-up data 
sheet, blood pressure (BP) measurements, and blood/urine 
sample collection.
An outline of the study protocol is shown in Figure 1 
and Table 1A. The study was approved by the Local 
Bioethical Committee (26/2015) and is registered on 
clinicaltrials.gov (NCT03243474; https://clinicaltrials.
gov/ct2/show/NCT03243474). Enrolment began on March 15, 
2017, and the study was registered on August 9, 2017. For 
further details see Supplement on-line (see journal website).
Study population
A total of 3000 individuals (both men and women) are 
planned to be enrolled in this part of the study. Unselected 
individuals aged ≥ 65 years will be included; the only exclu-
sion criterion is age < 65 years.
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Study questionnaires
The contents of the first visit questionnaire are outlined in 
Table 1B. The standardised Geriatric Depression Scale as-
sessment, planned for the second visit, consists of 15 ques-
tions. Additionally, the second visit questionnaire comprises 
10 questions focused on AF symptoms, fasting status, and 
any adverse events during the use of the ECG monitoring 
system. The third visit questionnaire includes 20 questions 
and is similar to the second visit one, with the addition of 
questions regarding outpatient visits, hospitalisations, and 
changes in medications. On the third visit, the Mini-Mental 
State Examination is completed as well. Finally, the fourth 
phone visit questionnaire involves 30 questions and gathers 
a similar scope of data as the third visit one but is expanded 
for survival status.
Table 1A. Schedule of assessments
Parameters Visit 1
Home visit
Visit 2 Visit 3 Visit 4
After 
10 days ± 4 days
After 
30 days ± 4 days
After 
1 year ± 7 days
Home visit Home visit Phone call
Informed consent √      
Monitoring NOMED ECG  
system installation
√      
ECG telemonitoring (PMP) Continuously Continuously Continuously
Monitoring system return     √  
Medical and social questionnaire √     √
Present status monitoring questionnaire   √ √ √
Adverse event monitoring questionnaire   √ √ √
Geriatric Depression Scale assessment   √    
Blood pressure measurements √ √ √  
Heart rate measurement √ √ √  
Anthropometric measurements √   √  
Blood and urine samples   √  
ECG — electrocardiogram; PMP — patient monitoring platform (Comarch Healhcare)
Table 1B. The first visit questionnaire
Data collected in the questionnaire
Demographic data (e.g. education, marital status, employment) 
Clinical symptoms and diseases 
Medications taken 
Medical history 
Awareness of cardiovascular risk factors
Family medical history in first-degree relatives
Detailed information on atrial fibrillation/flutter episodes  
(symptoms, duration, treatment, hospitalisations)
Habits (smoking, drinking)
Physical activity
Knowledge about health, disease, and prevention
Figure 1. Study workflow; ECG — electrocardiogram
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The levels of the following parameters are planned to be 
measured through laboratory tests performed from blood sam-
ples: sodium, potassium, chloride, total cholesterol, high-den-
sity lipoprotein cholesterol, low-density lipoprotein cholesterol 
(direct and calculated measurement), triglycerides, creatinine, 
estimated glomerular filtration rate (calculated according to 
the Modification of Diet in Renal Disease and Chronic Kidney 
Disease Epidemiology Collaboration), glucose, thyrotropin 
hormone, total bilirubin, aspartate aminotransferase, alanine 
aminotransferase, gamma glutamyl transpeptidase, alkaline 
phosphatase, haemoglobin A1c, high-sensitivity C-reactive 
protein, and N-terminal pro–B-type natriuretic peptide. The 
levels of creatinine, albumin, and albumin-to-creatinine ratio 
are planned to be tested from collected urine samples. 
Follow-up chart
The follow-up chart consists of two parts, the first concerned 
with AF and the second with adverse events during the 
follow-up period. The first part is to be filled out with data 
on symptomatology (European Heart Rhythm Association 
scale), approach to treatment (no treatment or rhythm/rate 
control), and methods used (drugs/ablation). The second part 
is designed to collect data on every potential adverse event, 
including unplanned hospitalisation, unscheduled outpatient 
visit, emergency service callout, or death, as well as its specifics 
(date, type, and a detailed description).
Endpoints
The primary endpoint is the prevalence of AF, especially the 
silent type, in Polish individuals aged ≥ 65 years. The second-
ary endpoint is to determine the independent risk factors for 
the occurrence of AF, especially the silent type. Additional 
endpoints include the prevalence of heart failure, stroke, 
hypertension, and vascular diseases.
Monitoring system
The non-invasive, long-term ECG monitoring system used in 
the study was developed by Comarch Healthcare (Krakow, 
Poland) based on the GSM technology. This system comprises 
a mobile long-term ECG vest with dry silver ECG electrodes, 
exchangeable recorders fixed to the vest, a docking station act-
ing as a charger, a GSM transmitter, and a patient monitoring 
platform for data analysis and storage. All study participants 
will be equipped with two recorders to maintain continuous 
ECG acquisition during charging and enable the transmission 
of data to the monitoring platform every 24 h. Participants 
will be trained on how to use the ECG monitoring device at 
the first visit by the study nurse. For further details refer to 
Supplement on-line (see journal website).
Statistical analysis
As the study will analyse equivalent age strata, the sam-
ple will not reflect the structure of the elderly population 
(age ≥ 65 years). After the end of the study, it is planned to 
calculate weighted adjustments for epidemiological analy-
ses. Statistical analyses of the data will be performed using 
SAS software for Windows (version 9.4, Cary, NC, USA) and 
R software for statistical computing (The R Foundation). Ba-
sic statistical analyses involving estimation of the indicators 
defined in the study objectives will be conducted using the 
SURVEYFREQ and SURVEYMEANS procedures of the SAS 
package, considering the complex sample and design.
DISCUSSION
Current guidelines recommend that AF screening be pro-
vided for all symptomatic individuals and for those who are 
asymptomatic but have a high risk for thromboembolism. 
AF screening may be performed using simple methods, e.g. 
pulse palpation or, in those with cardiac implanted electronic 
devices, using high atrial rate analysis during interrogation. 
Nevertheless, the AF diagnosis should always be confirmed 
by a standard ECG recording [7, 8].
A short-lasting, asymptomatic episode of AF may result 
in a 2.8-fold higher risk of ischaemic stroke and a 2.5-fold 
higher risk of fatality [9]. Among elderly individuals, episodes 
of arrhythmia are often mildly symptomatic or completely 
asymptomatic, which may significantly hinder the possibil-
ity of diagnosing the arrhythmia [10]. Fernandez et al. [11] 
showed that 24-h monitoring of individuals with acute-phase 
ischaemic stroke enables AF detection in as many as 10% of 
hospitalised patients. Grond et al. [3] determined that moni-
toring of individuals with a recent (occurring within the last 
72 h) ischaemic stroke is in direct correlation with a higher AF 
detection rate and thus results in earlier introduction of opti-
mal treatment and prevention. Early results of the PROFIL-AF 
study indicate that the simple action of taking the pulse and 
interviewing individuals regarding symptoms suggesting ar-
rhythmia enables AF detection, including an additional 3.4% 
of individuals aged > 65 years who had never before been 
diagnosed with AF. Studies reporting the incidence of silent 
AF have been summarised in Supplemental Table 1 (see 
journal website).
Such high detection rates were based on single tests 
performed in individuals, therefore it may be assumed that 
long-term monitoring would facilitate AF detection in larger 
groups. Episodes of clinically silent AF are strictly correlated 
with a higher frequency of a so-called silent stroke [12], as 
detected based on nuclear magnetic resonance imaging, with 
a prevalence of 8% to 28%. The main causes of silent stroke 
are AF (28%) and hypertension [13]. The silent stroke doubles 
the risk of dementia, especially among elderly individuals [14].
Thus, asymptomatic AF is an important and underestimat-
ed clinical issue. A correct and early diagnosis of arrhythmia 
would enable the introduction of the correct treatment and 
thereby would help to prevent thromboembolic complica-
tions by the use of oral anticoagulants [15]. Improvements in 
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the field of monitoring and detecting arrhythmia through the 
implementation of simple, easy-to-use, non-invasive devices 
capable of registering electric activity of the heart, perform-
ing preliminary rhythm analysis, and enabling long-term 
monitoring and remote data transmission may facilitate the 
diagnostic process. 
In conclusion, the NOMED-AF study will determine the 
true proportion of individuals with asymptomatic AF and help 
to ascertain the independent factors predisposing to this 
arrhythmia. The study will identify the population of older 
individuals requiring AF screening.
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